Have a personal or library account? Click to login
Design and development of novel 1,2,3-triazole chalcone derivatives as potential anti-osteosarcoma agents via inhibition of PI3K/Akt/mTOR signalling pathway Cover

Design and development of novel 1,2,3-triazole chalcone derivatives as potential anti-osteosarcoma agents via inhibition of PI3K/Akt/mTOR signalling pathway

Acta Pharmaceutica
Volume 72 (2022): Issue 3 (September 2022)
By: Qing Su,  Baolin Xu,  Zhoubin Tian and  Ziling Gong  
Open Access
|Apr 2022
DOI: https://doi.org/10.2478/acph-2022-0026 | Journal eISSN: 1846-9558 | Journal ISSN: 1330-0075
Journal RSS Feed
Language: English
Page range: 389 - 402
Accepted on: Dec 14, 2021
Published on: Apr 13, 2022
Published by: Croatian Pharmaceutical Society
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
1,2,3-triazole-chalcone hybrids,
osteosarcoma,
kinase inhibition
Related subjects:
Pharmacy,
Pharmacy, other

© 2022 Qing Su, Baolin Xu, Zhoubin Tian, Ziling Gong, published by Croatian Pharmaceutical Society
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Previous articleVolume 72 (2022): Issue 3 (September 2022)Next article